基石藥業-B(02616.HK)公佈中期業績,營收同比大增229.48%
格隆匯8月25日丨基石藥業-B(02616.HK)公佈中期業績,收入由截至2021年6月30日止六個月的人民幣7940萬元增加人民幣1.824億元至截至2022年6月30日止六個月的人民幣2.618億元(包括藥品銷售(指公司銷售藥品阿伐替尼、普拉替尼及新上市艾伏尼布)人民幣1.614億元、授權費收入人民幣8730萬元及舒格利單抗特許權使用費收入人民幣1310萬元),乃主要歸因於藥品阿伐替尼及普拉替尼的總銷售額以及來自新上市艾伏尼布及舒格利單抗收入的增加。
研發開支由截至2021年6月30日止六個月的人民幣5.128億元減少人民幣2.462億元至截至2022年6月30日止六個月的人民幣2.666億元,乃主要由於里程碑費用及第三方合約成本以及僱員成本降低。
期內虧損由截至2021年6月30日止六個月的人民幣7.739億元減少人民幣4.123億元至截至2022年6月30日止六個月的人民幣3.616億元,乃主要歸因於收入增加及研發開支減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.